Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Current Market Cap
View:
Post by Riverfolk on Feb 23, 2021 12:33pm

Current Market Cap

The recent sell off by a motivated ANON has placed the current market cap at pre-LSALT catalyst levels. $1.21 is:

-Pre-Health Canada Approval
-Pre-Turkish Ministry of Health Approval
-Pre- FDA Approval
-Pre-Government of Canada Funding
-Pre- Phase 2 trial Expansion 

The last straight equity financing was at $1.50
Comment by 2019champs on Feb 23, 2021 7:38pm
Excellent buying opportunity. Its one seller keeping us down unfortunately. Just need to take away his shares and then its lift off!
Comment by Riverfolk on May 18, 2021 1:10pm
In addition to my previous post, we are still currently trading below the last straight equity financing at $1.50 and the following has occured: -Additional Canadian hospitals added -Health Canada Ammended Phase II trial Protocol -Turkey Ministry of Health Approval for trial expansion -Licensing aggreement for Cilistatin  -Final Dosing of Phase II Metablok trial (65 patients enrolled)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities